Both CRSP and NTLA are advancing in vivo gene editing therapies targeting large markets, with financial stability supporting ...

New to Growth Stocks? Here's 1 Every Investor Should Have on Their Radar. CRISPR Therapeutics has an approved gene-editing ...

On one wall of endocrinologist Kevan Herold’s office hangs artwork by a girl who joined one of his type 1 diabetes trials when she was 11 years old. The girl was diagnosed with stage 2 of the disease, ...

Discover the top CRISPR companies driving innovation in gene editing, from biotech pioneers to promising start-ups shaping ...

Despite setbacks and funding cuts — and a quieting of the hype blaring its arrival — multiple CRISPR-based trials are ...

When six infants around the world were diagnosed with an odd trio of symptoms (diabetes, epilepsy, and abnormally small heads ...

Detailed price information for Crispr Therapeutics Ag (CRSP-Q) from The Globe and Mail including charting and trades.

Scientists discover a rare gene, TMEM167A, causing infant diabetes and neurological issues, unlocking new insights and ...

One of the most revolutionary tools in cutting-edge medicine is a molecular scalpel so precise that it can modify defective ...